Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.

NCT Number	NCT07546253
Lead Sponsor	NeuroOne Medical Technologies Corporation
Conditions	Drug Resistant Epilepsy, Refractory Epilepsy
Enrollment	100 participants
Start Date	2026-07
Primary Completion	2028-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-22